Selection
The inclusion criteria were as follows:
(1) Original investigation of intervention where causal inferences may be made. (2) Duration of the study of at least 2 months. (3) Primary or secondary outcome was a measure of glycemic control, i.e., HbA1c level, and the predictor was periodontal treatment. (4) Published between 1980 and January, 2005 , in the English language.
Data Abstraction
From each included study, three investigators independently extracted data regarding the study design, diabetes type, number of participants, duration of follow-up, treatment or intervention given, outcomes measures, confounding adjustment, and the results.
Study Characteristics
Most studies provided basic non-surgical periodontal therapy as the intervention. Some studies supplemented non-surgical periodontal debridement with chlorhexidine oral rinse or low-dose tetracycline or amoxicillin, systemically Rodrigues et al., 2003) or locally . Most studies reported change in HbA1c in %, but some studies reported the number of subjects at different levels of HbA1c (Christgau et al., 1998) . In such cases, we calculated the mean HbA1c by multiplying the number of subjects by the median value of that category, then dividing by the total number of subjects. Two studies reported an extremely small standard deviation (Grossi et al., 1997; Stewart et al., 2001) . For these studies, we imputed the mean standard deviation of all studies included in this metaanalysis, assuming homogeneity according to the Q-statistic.
Quantitative Data Synthesis
Utilizing Stata version 8.0, we estimated the treatment effect for individual trials by calculating the differences in mean HbA1c levels between the pre-and post-periodontal treatments. We assessed heterogeneity by the Q-statistic, and publication bias using a funnel plot and Egger's and Begg's tests (Egger et al., 2001) . We calculated the standard error of the weighted mean difference by pooling the variances in both groups, assuming equal variances on the basis of Q-statistic and taking the square root. We pooled data using the inverse variance method of weighting (for continuous outcomes) and using a random-effects model (DerSimonian and Laird, 1986) . Additionally, to assess the effect differences due to diabetes type, the type of control (i.e., self as control or parallel control), or the treatment modality (i.e., nonsurgical debridement vs. antibiotics administration), we conducted meta-regressions and stratified analyses.
RESULTS

Trial Flow
The flow diagram for the search process responsive to the consensus statement to Improve the Quality of Report of Metaanalysis (QUOROM) (Moher et al., 1999) is presented in Fig.  1 . The detailed search process is illustrated in the APPENDIX (Appendix Table 1 ).
Study Characteristics
We identified 370 titles from our search, and from these titles we selected 64 abstracts. All three investigators read 64 abstracts individually and selected 23 preliminary candidate studies. Full texts of these 23 studies were obtained and evaluated. Collectively, we selected 11 intervention studies as final candidates satisfying our inclusion criteria set a priori (Table 1 ) (Miller et al., 1992; Seppala and Ainamo, 1994; Aldridge et al., 1995; Smith et al., 1996; Westfelt et al., 1996; Grossi et al., 1997; Christgau et al., 1998; Iwamoto et al., 2001; Stewart et al., 2001; Rodrigues et al., 2003) . One of these 11 studies could not provide a numeric value of HbA1c and was excluded from analyses. Studies considered but excluded in this review and the reasons for exclusion are listed in the APPENDIX (Appendix Table 2 ).
Publication Bias
Egger's and Begg's tests yielded p-values of 0.69 and 0.81, respectively, indicating no consistent evidence of quantitative publication bias. In addition, the funnel plot demonstrated no clear visual evidence of bias (Appendix Fig.) .
Heterogeneity
The Q-statistic for testing heterogeneity was not significant. For all 10 studies, the Q-statistic = 0.32; for type 2 diabetes studies only (N = 5), Q = 0.18 (p = 0.99). Thus, all included studies were quite homogeneous, and fixed-effects and random-effects models yielded identical results.
Validity Assessment
Two reviewers evaluated each study's quality independently. The agreement rate was 89%. Agreement was defined as the difference in total quality scores between the reviewers being within one standard deviation. Criteria used for quality assessment were based on our previous quality score rubrics, modified to accommodate clinical trials in periodontal treatment (Janket et al., 2003 ) (Appendix Table 3 ). 
Quantitative Data Synthesis
Ten studies involving 456 type 1 and type 2 diabetic patients resulted in statistically non-significant decrease of HbA1c levels by 0.38% (Fig. 2) . The light and black squares designate the results from type 1 and type 2 diabetic patients, respectively, and a dotted square designates results from a type 1 and type 2 mixed group. Visual review of the graph suggests that there was a correlation between the diabetes type and the direction of outcomes. That is, the research that investigated type 2 diabetes mellitus (DM) appeared to generate stronger effects of periodontal treatment on HbA1c reduction than did the studies that examined predominantly the type 1 DM group. The result of meta-regression showed a non-significant decrease of 0.57% among type 2 DM patients only. The type of control did not manifest any substantial difference in the level of HbA1c (p = 0.82). The stratified analysis suggested that antibiotic treatment conferred 0.27% lower HbA1c level than that conferred by non-surgical debridement (-0.71% vs. -0.44%) (Table 2, Fig. 2) . Overall, the reduction in HbA1c levels was not significant, and we cannot reject the null hypothesis that "periodontal treatment does not affect glycemic control in diabetic patients".
DISCUSSION
Over all, this meta-analysis of 10 intervention studies found a non-significant 0.38% reduction in actual value of HbA1c, and 0.71% among 5 studies conducted among patients with type 2 diabetes. However, inflammation is implicated in the pathogenesis of type 2 diabetes; thus, including subjects with type 1 diabetes, where the pathogenesis is presumed to be an autoimmune process (Ludwig and Ebbeling, 2001) , might have attenuated the effects of periodontal treatment on glycemic control. Thus, restricting the summary results among type 2 diabetic patients may be more pertinent. When each study has a very small sample size, a meta-analysis may offer a better estimate of periodontal treatment than any individual study.
Some studies might have considered their mean as a population mean and used standard errors of the means rather than standard deviation Stewart et al., 2001) . Thus, their standard deviations were much smaller than those reported in other studies (standard deviations in parentheses): [Miller '92 (1.85) , Seppala '94 (1.77 ), Aldridge '95 (2.00), Westfelt '96 (2.00), Grossi '97 (0.6) , Christgau '98 (1.6), Stewart '01 (0.6), Iwamoto '01 (1.72), Rodrigues '03 (1.75) ]. To avoid erroneously amplifying the impact of these studies on the final summary of this meta-analysis, we imputed the average standard deviation of all the studies included in this meta-analysis.
Some studies were criticized for dispensing doxycycline systemically, and thus for potential bias due to the reduction of systemic CRP and other systemic pro-inflammatory mediators. Our results suggest, however, that doxycycline 10 mg, topically delivered in periodontal pockets , was more efficacious (10.5% decrease from pretreatment level) than systemic administration of doxycycline 100 mg/day (4.7% decrease from pre-treatment levels) in reducing HbA1c . In addition, we expected that local administration would have less serious and less frequent adverse events. These facts were not known prior to our systematic review and meta-analysis, and future investigators may wish to consult our recommendations in their respective studies.
Sixty percent of our samples studied predominantly type 1 DM patients who might not have displayed any noticeable changes in HbA1c, due to etiology and tighter control of insulin and HbA1c. Thus, restricting the summary results to type 2 diabetic patients who were not on an insulin regimen (we do not have this information) might elicit the true effects of periodontal treatment.
Studies with parallel comparison groups tended to show evidence of unbalanced randomization Rodrigues et al., 2003) . Clearly, the control group had better glycemic control at baseline, which was significant (Rodrigues et al., 2003) . In this case, adjusting for the baseline differences may be appropriate to differentiate the treatment effects from the effects due to baseline characteristics.
Recommendations for future studies are as follows: (1) Type 1 diabetes is presumed to originate from an autoimmune process (Ludwig and Ebbeling, 2001) , and is usually controlled by the administration of insulin. Glucose levels in these patients are very tightly monitored and adjusted frequently to prevent hypoglycemic crisis. Thus, any obvious change in HbA1c might not be evident, although it is possible that insulin requirements might have been lower. Further, type 1 diabetic patients in general may be too young to develop moderate to severe periodontitis. Thus, future study participants should be (Firatli, 1997; Beck et al., 1998) . Thus, the intervention should be rendered only to diabetic patients with the same type, similar duration after diagnosis, and similar baseline glycemic control. (6) The intervention should result in a clear improvement in periodontal health. Ineffective interventions may not be different from non-intervention. Also, amoxicillin administration, when causative agents are predominantly Gram-negative organisms, may elicit less efficacious results (Rodrigues et al., 2003) . Local doxycycline treatment targeted to periodontal tissue appeared to be most effective in reducing blood HbA1c levels . We postulated that local delivery of doxycycline would be associated with fewer adverse events. Our assumption was confirmed when we contacted the investigators of the study where doxycycline was delivered locally. They observed no adverse events among 13 patients in a month-long trial (personal communication via e-mail with Drs. Nishimura/Iwamoto). However, since this observation was drawn from a single study, further corroboration by future studies is necessary before we can make clear recommendations. Although sample size was larger (N = 140), the VA dental diabetes study documented adverse events with systemic doxycycline administration in 19% of the participants, and 16.4% (86% of all adverse events) showed mild to severe gastro-intestinal irritation (Jones et al., 2005) . Periodontal therapy with antibiotics appeared to decrease HbA1c levels by statistically non-significant 0.71% among patients with type 2 diabetes. Although this percent improvement in glycemic control may be of value to some patients, the evidence currently available was not strong enough for us to reject the null hypothesis, "periodontal treatment does not affect glycemic control in patients with diabetes". Further studies with a larger sample size among appropriate target populations and utilizing effective treatments are needed to discern whether there is a significant clinical benefit of periodontal therapy on blood sugar control in persons with type 2 diabetes.
